AN OPEN LABEL, RANDOMIZED, TWO TREATMENT, TWO PERIOD, SINGLE DOSE & MULTIPLE DOSE, TWO-ARM, TWO WAY CROSSOVER, STEADY STATE STUDY TO ASSESS THE PHARMACOKINETIC PROFILE AND COMPARE THE DPP-4 INHIBITION ACTIVITY OF VILDAGLIPTIN MR 100MG TABLET QD [TEST PRODUCT (A)] OF NOVARTIS HEALTHCARE PVT LTD, INDIA WITH VILDAGLIPTIN 50 MG IR TABLETS BID [REFERENCE PRODUCT (B)] OF NOVARTIS HEALTHCARE PVT. LTD, INDIA IN HEALTHY ADULT, HUMAN SUBJECTS, UNDER FASTING CONDITIONS.
Latest Information Update: 27 Nov 2020
At a glance
- Drugs Vildagliptin (Primary)
- Indications Type 1 diabetes mellitus; Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Novartis India Limited
- 27 Nov 2020 New trial record